Global Progress in Reducing HIV Infections Ahead of World AIDS Day: A Call for Action

Global HIV infections and deaths are decreasing, indicating progress in addressing the disease. However, health experts remind us that HIV is still a significant issue, especially ahead of World AIDS Day.

Progress and Challenges

A study published in The Lancet HIV reveals that the number of new HIV infections worldwide fell by 20% during the 2010s. This decline mainly occurred in sub-Saharan Africa, the region most affected by HIV. In contrast, areas like Eastern Europe and the Middle East experienced increases in HIV cases.

The lead author of the study, Hmwe Kyu, noted that over one million people still acquire HIV each year. Among the 40 million individuals living with HIV, about 25% do not receive treatment.

Effective Treatment Options

Pre-exposure prophylaxis (PrEP) has proven to be an effective preventative treatment that can reduce the risk of getting HIV from sex by approximately 99%. Some countries, like France, are advocating for broader access to PrEP, emphasizing its availability for anyone who may need it.

For those already infected, antiretroviral therapy can lower the virus’s presence in the blood to undetectable levels. This significantly reduces the chance of transmission from mother to child during breastfeeding.

New Hope with Lenacapavir

A new drug called lenacapavir shows promise in preventing HIV infections. It requires only two injections per year, a significant improvement over daily pills. However, the high cost of lenacapavir, around $40,000 per year in some regions, raises concerns about accessibility.

Researchers suggest that lenacapavir could be produced for as little as $40. Gilead, the manufacturer, has signed agreements with generic drug companies to distribute the drug in lower-income countries, although many countries remain excluded from these agreements.

The twice-yearly injection may also help reduce the stigma associated with HIV treatment.

Vaccine Development

Despite extensive research, an HIV vaccine is still not available. However, lenacapavir is being referred to as “like having a vaccine” due to its effectiveness. Some patients have achieved cures for HIV, but these cases often require severe procedures like stem cell transplants, making them impractical for the majority.

In summary, although there is progress in reducing HIV infections and improving treatment options, significant challenges remain. Continued efforts are essential to ensure that effective treatments are accessible to all, particularly in the hardest-hit regions.